Equities research analysts expect Stealth BioTherapeutics Corp (NASDAQ:MITO) to post ($0.02) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Stealth BioTherapeutics’ earnings. Stealth BioTherapeutics posted earnings of ($0.04) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 50%. The business is scheduled to report its next earnings report on Thursday, May 6th.
On average, analysts expect that Stealth BioTherapeutics will report full-year earnings of ($0.09) per share for the current fiscal year, with EPS estimates ranging from ($0.10) to ($0.07). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Stealth BioTherapeutics.
Stealth BioTherapeutics (NASDAQ:MITO) last announced its quarterly earnings data on Monday, April 5th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.04).
Institutional investors and hedge funds have recently bought and sold shares of the business. Mercer Global Advisors Inc. ADV acquired a new stake in Stealth BioTherapeutics in the fourth quarter worth $75,000. Renaissance Technologies LLC raised its holdings in Stealth BioTherapeutics by 536.5% in the fourth quarter. Renaissance Technologies LLC now owns 568,164 shares of the company’s stock worth $849,000 after purchasing an additional 478,903 shares during the period. Susquehanna International Group LLP acquired a new stake in Stealth BioTherapeutics in the fourth quarter worth $41,000. Finally, Virtu Financial LLC acquired a new stake in shares of Stealth BioTherapeutics during the fourth quarter worth $67,000. Institutional investors own 1.19% of the company’s stock.
MITO traded down $0.01 during mid-day trading on Friday, hitting $1.42. The stock had a trading volume of 2,045 shares, compared to its average volume of 422,895. The stock’s fifty day simple moving average is $1.72 and its 200-day simple moving average is $1.54. The firm has a market capitalization of $78.72 million, a price-to-earnings ratio of 35.76 and a beta of 2.25. Stealth BioTherapeutics has a 1-year low of $1.19 and a 1-year high of $2.58.
About Stealth BioTherapeutics
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
Featured Article: Why does the United States have a lingering trade deficit?
Get a free copy of the Zacks research report on Stealth BioTherapeutics (MITO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.